UNSPSC 51273905: Atropine/morphine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN205. This VA Drug Class (CN205) classifies this compound as belonging to the group ANESTHETIC ADJUNCTS.

UNSPSC 51273905 Atropine/morphine is a Commodity code that encompasses emergency medical and public health pharmaceuticals procured by state and local jurisdictions for community health, emergency response, and opioid mitigation programs. Recent state and local solicitations under this code show demand for naloxone, opioid antagonists, and associated drug deactivation systems rather than atropine or morphine specifically; the actual purchasing activity centers on narcotics reversal agents and harm-reduction pharmaceuticals for county health departments and state health agencies. Issuing bodies include county public health departments, state health and human services commissions, and multistate cooperative purchasing alliances representing multiple states and municipalities. The work involves procuring finished pharmaceutical products in bulk quantities with quarterly or ongoing delivery schedules to specified public health facilities, requiring vendors to meet DEA authorization, FDA compliance, cGMP certification, and Drug Supply Chain Security Act (DSCSA) adherence.

Recent activity appears concentrated in Florida and the multistate cooperative purchasing arena, with a secondary emerging focus in Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building in Sanford, due July 26, 2023, on a two-year contract with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026; this procurement emphasizes price competitiveness (75 percent weight), compliance with cGMP and DSCSA, and relationships with authorized wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, gathering market intelligence on direct-to-manufacturer pharmaceutical prescriptions outside traditional PBM and GPO channels, signaling potential future state-level demand for alternative pharmaceutical distribution models.